Nicotinic acid receptor agonists impair myocardial contractility by energy starvation
William D Watson1, Kerstin N Timm2, Andrew J Lewis1
1Department of Cardiovascular Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, UK.
Abstract:
Nicotinic acid receptor agonists have previously been shown to cause acute reductions in cardiac contractility. We sought to uncover the changes in cardiac metabolism underlying these alterations in function. In nine humans, we recorded cardiac energetics and function before and after a single oral dose of nicotinic acid using cardiac MRI to demonstrate contractile function and Phosphorus-31 (31 P) magnetic resonance spectroscopy to demonstrate myocardial energetics. Nicotinic Acid 400 mg lowered ejection fraction by 4% (64 ± 8% to 60 ± 7%, P = .03), and was accompanied by a fall in phosphocreatine/ATP ratio by 0.4 (2.2 ± 0.4 to 1.8 ± 0.1, P = .04). In four groups of eight Wistar rats, we used pyruvate dehydrogenase (PDH) flux studies to demonstrate changes in carbohydrate metabolism induced by the nicotinic acid receptor agonist, Acipimox, using hyperpolarized Carbon-13 (13 C) magnetic resonance spectroscopy. In rats which had been starved overnight, Acipimox caused a fall in ejection fraction by 7.8% (67.5 ± 8.9 to 60 ± 3.1, P = .03) and a nearly threefold rise in flux through PDH (from 0.182 ± 0.114 to 0.486 ± 0.139, P = .002), though this rise did not match pyruvate dehydrogenase flux observed in rats fed carbohydrate rich chow (0.726 ± 0.201). In fed rats, Acipimox decreased pyruvate dehydrogenase flux (to 0.512 ± 0.13, P = .04). Concentration of plasma insulin fell by two-thirds in fed rats administered Acipimox (from 1695 ± 891 ng/L to 550 ± 222 ng/L, P = .005) in spite of glucose concentrations remaining the same. In conclusion, we demonstrate that nicotinic acid receptor agonists impair cardiac contractility associated with a decline in cardiac energetics and show that the mechanism is likely a combination of reduced fatty acid availability and a failure to upregulate carbohydrate metabolism, essentially starving the heart of fuel.
Insights
Nicotinic acid receptor agonists reduce heart contractility by impairing cardiac energetics. This occurs due to reduced fatty acid availability and a failure to increase carbohydrate metabolism, essentially starving the heart of fuel.
Area of Science:
- Cardiology
- Metabolic Medicine
- Biochemistry
Background:
- Nicotinic acid receptor agonists are known to acutely reduce cardiac contractility.
- The underlying changes in cardiac metabolism responsible for these functional alterations require further investigation.
Purpose of the Study:
- To investigate the effects of nicotinic acid on cardiac energetics and function in humans.
- To explore the impact of a nicotinic acid receptor agonist (Acipimox) on carbohydrate metabolism and cardiac function in rats.
Main Methods:
- Cardiac MRI and Phosphorus-31 (31P) magnetic resonance spectroscopy were used in humans to assess cardiac function and energetics.
- Pyruvate dehydrogenase (PDH) flux studies using hyperpolarized Carbon-13 (13C) magnetic resonance spectroscopy were conducted in rats.
Main Results:
- In humans, nicotinic acid (400 mg) reduced ejection fraction and the phosphocreatine/ATP ratio.
- In fasted rats, Acipimox decreased ejection fraction and significantly increased PDH flux.
- In fed rats, Acipimox decreased PDH flux and plasma insulin levels, despite stable glucose concentrations.
Conclusions:
- Nicotinic acid receptor agonists impair cardiac contractility and energetics.
- The mechanism involves reduced fatty acid availability and impaired upregulation of carbohydrate metabolism, leading to cardiac "starvation".
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Cholinergic Receptors: Nicotinic
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Drugs Acting on Autonomic Ganglia: Blockers


